FRAT1 抗体 (AA 161-260) (Cy7)
-
- 抗原 See all FRAT1 抗体
- FRAT1 (Frequently Rearranged in Advanced T-Cell Lymphomas (FRAT1))
-
抗原表位
- AA 161-260
-
适用
- 人
-
宿主
- 兔
-
克隆类型
- 多克隆
-
标记
- This FRAT1 antibody is conjugated to Cy7
-
应用范围
- Western Blotting (WB), Immunofluorescence (Cultured Cells) (IF (cc)), Immunofluorescence (Paraffin-embedded Sections) (IF (p))
- 预测反应
- Human,Mouse,Rat,Dog,Cow
- 纯化方法
- Purified by Protein A.
- 免疫原
- KLH conjugated synthetic peptide derived from human FRAT1
- 亚型
- IgG
- Top Product
- Discover our top product FRAT1 Primary Antibody
-
anti-Frequently Rearranged in Advanced T-Cell Lymphomas (FRAT1) (AA 181-279) antibody
FRAT1 适用: 人 WB, ELISA 宿主: 小鼠 Monoclonal 7C9 unconjugated
anti-Frequently Rearranged in Advanced T-Cell Lymphomas (FRAT1) (C-Term) antibodyFRAT1 适用: 人 WB, IHC, ELISA 宿主: 兔 Polyclonal unconjugated
anti-Frequently Rearranged in Advanced T-Cell Lymphomas (FRAT1) (AA 99-128) antibodyFRAT1 适用: 人 WB, IHC (p) 宿主: 兔 Polyclonal unconjugated
anti-Frequently Rearranged in Advanced T-Cell Lymphomas (FRAT1) (AA 244-274), (C-Term) antibodyFRAT1 适用: 人 WB, IHC (p) 宿主: 兔 Polyclonal unconjugated
anti-Frequently Rearranged in Advanced T-Cell Lymphomas (FRAT1) (C-Term) antibodyFRAT1 适用: 人 WB, IHC (p), EIA 宿主: 兔 Polyclonal unconjugated
-
- 应用备注
-
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200 - 限制
- 仅限研究用
-
- 状态
- Liquid
- 浓度
- 1 μg/μL
- 缓冲液
- Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.
- 储存液
- ProClin
- 注意事项
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.
- 储存条件
- -20 °C
- 储存方法
- Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
- 有效期
- 12 months
-
- 抗原
- FRAT1 (Frequently Rearranged in Advanced T-Cell Lymphomas (FRAT1))
- 别名
- FRAT1 (FRAT1 产品)
- 背景
-
Synonyms: FRAT 1, frequently rearranged in advanced T cell lymphomas, Frequently rearranged in advanced T-cell lymphomas, GSK 3 binding protein FRAT1, proto oncogene FRAT1, FRAT1_HUMAN.
Background: FRAT1 and FRAT2 were originally characterized as proteins frequently rearranged in advanced T cell lymphoma, and they have since been identified as proto-oncogenes involved in tumorigenesis. These proteins share significant homology with the Xenopus glycogen synthase kinase-3 (xGSK-3) binding protein, which is designated GBP and is essential for the formation of the dorsal-ventral axis during embryonic development. Establishment of these embryonic axes is mediated by the Wnt intracellular signaling pathway. Wnt signaling is regulated in part by the activity of GSK-3, which phosphorylates and thereby facilitates the degradation of ?catenin. GBP binds to GSK-3 and inhibits this phosphorylation, resulting in the accumulation of ?catenin and the subsequent transcription of Wnt target genes. Like GBP, FRAT2 has been shown to bind xGSK-3, suggesting that FRAT1 and FRAT2 may be GSK-3 regulatory proteins.
- 基因ID
- 10023
-
